Chad Watkins
General Manager - Isotope Strategy Telix Pharmaceuticals
Seminars
Wednesday 22nd July 2026
Securing a Supply of Isotopes Including At-211, Pb-212 & Tb-161 Within a Radioisotope Agnostic Portfolio
12:00 pm
- Advancing At-211, Pb-212 & Tb-161 as next-generation isotopes and their potential to transform targeted radioligand therapy
- Strengthening global production and partnership networks to ensure reliable, scalable supply
- Addressing the challenges of introducing a novel isotope in the absence of extensive clinical data while maintaining supply chain integrity
